Home > Products > Protein Tyrosine Kinase > EGFR > Olmutinib

Olmutinib

(CAS No:1353550-13-6)

Olmutinib is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). Also a potent inhibitor of Bruton's tyrosine kinase.

CAS No:1353550-13-6

Molecular Weight(MW):486.59

Purity:99.00%

Specification:500MG;1G;5G;10G;50G;100G

Price and large packaging, please e-mail consultation:info@SuperLan-chem.com

QC Documents

COA	MSDS	HPLC	NMR

ChemicalInfomation

CAS No:	1353550-13-6
Molecular formula(MF)	C₂₆H₂₆N₆O₂S
Molecular Weight(MW):	486.59
Alias

Solubility

In vitro	DMSO	97 mg/mL (199.34 mM)
	Ethanol	23 mg/mL (47.26 mM)
	Water	<1 mg/mL
In vivo

Biological Activity

Description

Olmutinib is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). Also a potent inhibitor of Bruton's tyrosine kinase.

Targets

mutant EGFR ^[1]

In vitro

HM61713 causes potent inhibition in cell lines H1975 (L858R and T790M) and HCC827 (exon 19 deletion). It has a low potency for NSCLC cell line H358 harboring wild-type EGFR (GI50 of 2225 nM)^[1].

In vivo

HM61713 has a half-life of over 24 h for EGFR inhibition. In the in vivo studies of xenograft models with grafts of H1975 and HCC827, HM61713 is active against the tumors without showing any side effects^[1].